Dr. Olatunji Alese
Claim this profileEmory University Hospital/Winship Cancer Institute
Studies Gastroesophageal Junction Adenocarcinoma
Studies Colorectal Cancer
16 reported clinical trials
41 drugs studied
Area of expertise
1Gastroesophageal Junction Adenocarcinoma
Stage IV
Stage III
BRAF negative
2Colorectal Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Olatunji Alese is currently running
TAS-102 + Nanoliposomal Irinotecan
for Gastrointestinal Cancer
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Recruiting1 award Phase 1 & 225 criteria
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
More about Olatunji Alese
Clinical Trial Related6 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Olatunji Alese has experience with
- Nab-paclitaxel
- Gemcitabine
- Irinotecan
- Regorafenib
- Cetuximab
- Dostarlimab
Breakdown of trials Olatunji Alese has run
Gastroesophageal Junction Adenocarcinoma
Colorectal Cancer
Pancreatic Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Olatunji Alese specialize in?
Olatunji Alese focuses on Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer. In particular, much of their work with Gastroesophageal Junction Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Olatunji Alese currently recruiting for clinical trials?
Yes, Olatunji Alese is currently recruiting for 7 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Olatunji Alese has studied deeply?
Yes, Olatunji Alese has studied treatments such as Nab-paclitaxel, Gemcitabine, Irinotecan.
What is the best way to schedule an appointment with Olatunji Alese?
Apply for one of the trials that Olatunji Alese is conducting.
What is the office address of Olatunji Alese?
The office of Olatunji Alese is located at: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory University Hospital/Winship Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.